Cognition Therapeutics is set to report topline data from its Phase 2 trial in Alzheimer's disease in mid-2024.CT1812, the company's lead drug candidate, is a sigma-2 receptor antagonist for Alzheimer...
Source LinkCognition Therapeutics is set to report topline data from its Phase 2 trial in Alzheimer's disease in mid-2024.CT1812, the company's lead drug candidate, is a sigma-2 receptor antagonist for Alzheimer...
Source Link
Comments